Practical Review of the Current Management of Fournier’s Gangrene

Abstract

Our review includes a total patient pool of 11,069 (Table 1). Most of the studies (n = 104) were retrospective

Fournier’s Gangrene: A Coexistence or Consanguinity of SGLT-2 Inhibitor Therapy

“…Emergent surgical debridement, broad-spectrum antibiotics, and appropriate resuscitation with intravenous fluids and vasopressor medications are the cornerstones of FG therapy [40,41]. This is in conjunction with controlling any other ongoing medical emergency that might have contributed to the development of FG.…”

“…This is in conjunction with controlling any other ongoing medical emergency that might have contributed to the development of FG. For example, a substantial number of patients with developing FG will present with diabetic ketoacidosis; since poorer glycemic control correlates with increasingly aggressive FG progression, strict control over blood sugars is required [41].…”

“…The use of the sFGSI is particularly useful in high-risk patients as early identification can lead to early intervention and therefore reduce the mortality rate. One study found that early intervention with the use of this scoring system was able to reduce mortality from 68.8% in those with later intervention to 23.8% in those with earlier intervention [41].…”

“…Earlier identification of FG can also decrease the severity of disease progression and reduce the potential body surface area affected [41].…”

“…The goal for patient outcomes in those with FG is to save the patient from sepsis and to minimize sexual and urinary dysfunction as much as possible [27]. While prompt patient admission and treatment with broadspectrum antibiotics are indicated, the most definitive treatment of FG is aggressive surgical debridement of necrotic tissues [25,41]. Since the optimal window for surgery from the time of presentation is approximately 14.3 hours, earlier identification will allow for adequate activation of surgical management in a timely manner [31,41].…”